Fundraising Fox

Luminary Therapeutics

Minneapolis, US · Founded 2019 · Delaware corporation · 1 known investors

BiotechHealthtechMedical Devices

Founders & leadership

Luminary Therapeutics was founded in 2019 by David Largaespada.

DL
David LargaespadaFounder
JLJeff Liter
Jeff LiterNamed on SEC filing
JH
James HaymakerNamed on SEC filing

Board

JRJeff Ross
Jeff RossBoard director
JWJohn Wells
John WellsBoard director
TLTracey Lodie
Tracey LodieBoard director
MCMark Chance
Mark ChanceBoard director

Investors · 1

CWRU Technology VenturesCleveland · $50K – $250K

Reported raises · per SEC filings

Form D private placements

$14.5M disclosed across 6 rounds · 2019–2025

▶$1.4MraisedNov 2025 · 6 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Branden MoriarityDirector
  • Mark ChanceDirector
  • Tracey LodieDirector
  • James HaymakerDirector, Promoter
  • John WellsDirector
  • Jeff RossDirector
  • Jeff LiterExecutive Officer, Director, Promoter
Offering amount
$12.4M
Amount sold
$1.4M
First sale
Oct 2025
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$5.2MraisedJan 2025 · 49 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Tracey LodieDirector
  • Jeff LiterExecutive Officer, Director, Promoter
  • Jeff RossDirector
  • James HaymakerDirector, Promoter
  • Mark ChanceDirector
  • John WellsDirector
Offering amount
$5.5M
Amount sold
$5.2M
First sale
Sep 2022
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$5.2MraisedJan 2025 · 48 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Jeff RossDirector
  • Jeff LiterExecutive Officer, Director, Promoter
  • John WellsDirector
  • James HaymakerDirector, Promoter
  • Tracey LodieDirector
  • Mark ChanceDirector
Offering amount
$5.9M
Amount sold
$5.2M
First sale
Nov 2024
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$375KraisedNov 2021 · 3 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Jim HaymakerDirector
  • David LargaespadaExecutive Officer, Director, Promoter
  • Jeff LiterExecutive Officer, Director, Promoter
  • John WellsDirector
  • Tracey LodieDirector
  • George CoxDirector
Offering amount
$1.5M
Amount sold
$375K
First sale
Oct 2021
Incorporated
Corporation, Delaware, 2019
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$825KraisedFeb 2021 · 11 investors · Biotechnology
Officers, directors & promoters on the filing
  • Jim HaymakerDirector
  • Tracey LodieDirector
  • George CoxDirector
  • John WellsDirector
  • Jeff LiterExecutive Officer, Director, Promoter
  • David LargaespadaExecutive Officer, Director, Promoter
Offering amount
$1M
Amount sold
$825K
First sale
Jan 2021
Incorporated
Corporation, Delaware, 2019
Federal exemptions
04
Full filing on SEC EDGAR ↗
▶$1.5MraisedNov 2019 · 11 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • David LargaespadaExecutive Officer, Director, Promoter
  • Jeff LiterExecutive Officer, Director, Promoter
Offering amount
$1.5M
Amount sold
$1.5M
First sale
Oct 2019
Incorporated
Corporation, Delaware, 2019
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Competitors · 2

by search overlap
Kite Pharma23 shared keywordsKite Pharma develops CAR T-cell therapies for cancer patients, engineering the immune system's cells to target and attack cancer. Each therapy is individualized per patient through a multi-step manufacturing process.
Solu22 shared keywordsSolu Therapeutics is a clinical-stage biotech developing a class of antibody therapeutics that link bifunctional small molecules to proprietary effector antibodies (its CyTAC and TicTAC platforms) to reach cell surface targets like GPCRs and ion channels. Its pipeline targets oncology, immunology and inflammation, and pain, with a lead program in Phase 1 trials for chronic myelomonocytic leukemia.

Companies competing with Luminary Therapeutics for the same Google search keywords, organic and paid, via search-intersection analysis.

In the news

Cell Therapy Financing Beyond CAR-T: Modality Diversification & M&A Analysisalacrita.com · Feb 2026Luminary Therapeutics Innovative Work at VTCRCvtcrc.com · Apr 2025Luminary Therapeutics to Develop Allogeneic CAR T Therapy for Targeting Solid Tumorsfinance.yahoo.com · Mar 2025Luminary Spotlight - Luminary Therapeuticsluminarytx.com · Jun 2020About Us - Luminary Therapeuticsluminarytx.com · Jun 2020

Frequently asked questions

Who founded Luminary Therapeutics?
Luminary Therapeutics was founded by David Largaespada in 2019.
Who are Luminary Therapeutics's investors?
Luminary Therapeutics's investors include CWRU Technology Ventures.
How much funding has Luminary Therapeutics raised?
Luminary Therapeutics has disclosed $14.5M raised across 6 rounds.
Where is Luminary Therapeutics headquartered?
Luminary Therapeutics is headquartered in Minneapolis, US.